Nilotinib treatment induced large granular lymphocyte expansion and maintenance of longitudinal remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia - Hagihara, Masao; Hua, Jian; Inoue, Morihiro; Uchida, Tomoyuki; Ide, Shiro; Ohara, Shin; Takaku, Tomoiku (International Journal of Hematology, 2020)
Keywords: Acute lymphoblastic leukemia; Aged; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone marrow; Case Report; CD57 antigen; CD57 Antigens; CD8 antigen; CD8-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes - immunology; Central nervous system; Chemotherapy; Chromosomes; Cytotoxicity; Dasatinib; Enzyme inhibitors; Expansion; Hematology; Humans; Immunology; Inhibitor drugs; Kinases; Leukemia; Lymphatic leukemia; Lymphocytes; Lymphocytes - immunology; Lymphocytes T; Lymphocytosis; Medicine; Medicine & Public Health; Multiagent systems; Neoplasm Recurrence, Local; Oncology; Patients; Peripheral blood; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology; Protein-tyrosine kinase; Pyrimidines; Pyrimidines - administration & dosage; Remission; Remission (Medicine); Remission Induction; Targeted cancer therapy; Time Factors; Treatment Outcome; Tyrosine; Nilotinib; LGLs; Remission; CD57; Ph-ALL